| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 132 | 2023 | 4980 | 12.500 |
Why?
|
| Carcinoma, Pancreatic Ductal | 35 | 2023 | 1510 | 5.250 |
Why?
|
| Adenocarcinoma | 38 | 2023 | 6324 | 3.490 |
Why?
|
| ABO Blood-Group System | 11 | 2017 | 361 | 2.140 |
Why?
|
| Bile Duct Neoplasms | 4 | 2023 | 580 | 1.340 |
Why?
|
| Colorectal Neoplasms | 23 | 2021 | 6592 | 1.210 |
Why?
|
| Cholangiocarcinoma | 3 | 2021 | 526 | 1.190 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 24 | 2023 | 11236 | 1.080 |
Why?
|
| Genome-Wide Association Study | 33 | 2022 | 11940 | 1.020 |
Why?
|
| Early Detection of Cancer | 6 | 2022 | 2939 | 0.970 |
Why?
|
| Polymorphism, Single Nucleotide | 32 | 2021 | 15603 | 0.900 |
Why?
|
| Genetic Predisposition to Disease | 33 | 2022 | 17409 | 0.870 |
Why?
|
| Bile Ducts, Intrahepatic | 2 | 2014 | 287 | 0.850 |
Why?
|
| Aged | 97 | 2023 | 162448 | 0.770 |
Why?
|
| Diabetes Complications | 4 | 2020 | 1397 | 0.770 |
Why?
|
| Vitamin D | 7 | 2020 | 3193 | 0.770 |
Why?
|
| Middle Aged | 108 | 2023 | 214639 | 0.750 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2021 | 194 | 0.750 |
Why?
|
| Tumor Microenvironment | 9 | 2023 | 3054 | 0.740 |
Why?
|
| Proportional Hazards Models | 21 | 2021 | 12456 | 0.730 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2020 | 3149 | 0.730 |
Why?
|
| Telomerase | 4 | 2017 | 736 | 0.730 |
Why?
|
| Biliary Tract Neoplasms | 3 | 2023 | 176 | 0.730 |
Why?
|
| Liver Neoplasms | 7 | 2022 | 4103 | 0.720 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2022 | 636 | 0.720 |
Why?
|
| Amino Acids, Branched-Chain | 3 | 2016 | 243 | 0.690 |
Why?
|
| Prospective Studies | 44 | 2023 | 51315 | 0.680 |
Why?
|
| Humans | 202 | 2023 | 715777 | 0.670 |
Why?
|
| Male | 128 | 2023 | 350324 | 0.650 |
Why?
|
| Case-Control Studies | 33 | 2021 | 21797 | 0.650 |
Why?
|
| Risk Factors | 61 | 2023 | 70866 | 0.650 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 8 | 2021 | 1634 | 0.630 |
Why?
|
| Fluorouracil | 10 | 2022 | 1610 | 0.630 |
Why?
|
| Gastroenteritis | 2 | 2009 | 258 | 0.630 |
Why?
|
| Jews | 1 | 2019 | 370 | 0.630 |
Why?
|
| Female | 128 | 2023 | 377204 | 0.610 |
Why?
|
| Leukocytes | 3 | 2021 | 2092 | 0.600 |
Why?
|
| Camptothecin | 7 | 2017 | 551 | 0.590 |
Why?
|
| Tricarboxylic Acids | 1 | 2016 | 31 | 0.590 |
Why?
|
| Iron Regulatory Protein 1 | 1 | 2016 | 39 | 0.580 |
Why?
|
| Organoplatinum Compounds | 5 | 2017 | 429 | 0.570 |
Why?
|
| Myeloid Cells | 1 | 2020 | 780 | 0.570 |
Why?
|
| Eosinophilia | 2 | 2009 | 510 | 0.550 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2018 | 4647 | 0.540 |
Why?
|
| Receptors, Leptin | 1 | 2016 | 342 | 0.540 |
Why?
|
| Disease-Free Survival | 11 | 2020 | 7015 | 0.530 |
Why?
|
| Medical History Taking | 1 | 2019 | 801 | 0.530 |
Why?
|
| Body Composition | 4 | 2022 | 2395 | 0.530 |
Why?
|
| Pancreatectomy | 5 | 2020 | 824 | 0.520 |
Why?
|
| Pancreas | 7 | 2022 | 1683 | 0.520 |
Why?
|
| Odds Ratio | 14 | 2017 | 9984 | 0.510 |
Why?
|
| Genomics | 3 | 2023 | 5342 | 0.510 |
Why?
|
| Deoxycytidine | 5 | 2019 | 825 | 0.500 |
Why?
|
| Sirolimus | 3 | 2013 | 1560 | 0.500 |
Why?
|
| Oligopeptides | 2 | 2018 | 1236 | 0.500 |
Why?
|
| Aged, 80 and over | 35 | 2022 | 58323 | 0.490 |
Why?
|
| Genetic Loci | 7 | 2017 | 2615 | 0.480 |
Why?
|
| Peritoneal Neoplasms | 2 | 2020 | 627 | 0.480 |
Why?
|
| Chromosomes, Human, Pair 5 | 5 | 2017 | 410 | 0.470 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2021 | 5412 | 0.470 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2020 | 8896 | 0.460 |
Why?
|
| Adult | 69 | 2023 | 212266 | 0.460 |
Why?
|
| Stomach Neoplasms | 3 | 2020 | 1245 | 0.450 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 1 | 2012 | 74 | 0.450 |
Why?
|
| Gene Expression Regulation, Neoplastic | 14 | 2023 | 8571 | 0.450 |
Why?
|
| Diabetes Mellitus | 6 | 2020 | 5463 | 0.450 |
Why?
|
| Survival Analysis | 11 | 2021 | 10499 | 0.440 |
Why?
|
| Leucovorin | 8 | 2022 | 596 | 0.430 |
Why?
|
| Antineoplastic Agents | 12 | 2020 | 13626 | 0.430 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 1192 | 0.420 |
Why?
|
| Cohort Studies | 30 | 2022 | 40029 | 0.420 |
Why?
|
| Exosomes | 1 | 2015 | 403 | 0.420 |
Why?
|
| ras Proteins | 2 | 2014 | 1102 | 0.410 |
Why?
|
| Antibodies, Monoclonal | 7 | 2023 | 9548 | 0.410 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 2 | 2008 | 126 | 0.400 |
Why?
|
| Inflammation | 4 | 2022 | 10081 | 0.400 |
Why?
|
| Jejunum | 2 | 2009 | 502 | 0.390 |
Why?
|
| Neoadjuvant Therapy | 7 | 2022 | 2556 | 0.390 |
Why?
|
| Adipose Tissue | 2 | 2019 | 3225 | 0.390 |
Why?
|
| Smoking | 8 | 2021 | 8980 | 0.390 |
Why?
|
| Genetic Variation | 6 | 2018 | 6664 | 0.380 |
Why?
|
| Hydroxychloroquine | 1 | 2014 | 411 | 0.380 |
Why?
|
| Mutation | 12 | 2021 | 29291 | 0.380 |
Why?
|
| Gene Expression Profiling | 4 | 2020 | 9504 | 0.380 |
Why?
|
| Neoplasm Proteins | 3 | 2018 | 3741 | 0.380 |
Why?
|
| Body Mass Index | 13 | 2023 | 12535 | 0.370 |
Why?
|
| Phenylurea Compounds | 1 | 2013 | 548 | 0.370 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 3 | 2008 | 426 | 0.370 |
Why?
|
| Exons | 2 | 2021 | 2466 | 0.360 |
Why?
|
| Multivariate Analysis | 10 | 2019 | 12480 | 0.360 |
Why?
|
| Quantitative Trait Loci | 4 | 2021 | 1976 | 0.360 |
Why?
|
| Genotype | 16 | 2021 | 12919 | 0.360 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 1744 | 0.360 |
Why?
|
| Weight Loss | 1 | 2020 | 2515 | 0.360 |
Why?
|
| Alleles | 8 | 2017 | 7099 | 0.350 |
Why?
|
| Chromosomes, Human, Pair 13 | 3 | 2016 | 203 | 0.350 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2020 | 6722 | 0.350 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2010 | 648 | 0.350 |
Why?
|
| Neoplasm Metastasis | 11 | 2022 | 5074 | 0.340 |
Why?
|
| Leptin | 1 | 2016 | 1573 | 0.340 |
Why?
|
| Survival Rate | 12 | 2020 | 13206 | 0.340 |
Why?
|
| Somatomedins | 1 | 2008 | 196 | 0.340 |
Why?
|
| Follow-Up Studies | 16 | 2022 | 39300 | 0.340 |
Why?
|
| Quinolines | 1 | 2013 | 738 | 0.330 |
Why?
|
| Metabolome | 2 | 2020 | 871 | 0.330 |
Why?
|
| Prognosis | 14 | 2023 | 29005 | 0.320 |
Why?
|
| Insulin | 6 | 2019 | 6651 | 0.320 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2022 | 20356 | 0.320 |
Why?
|
| Mosaicism | 3 | 2016 | 447 | 0.320 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 2280 | 0.310 |
Why?
|
| Chromosomes, Human, Pair 2 | 2 | 2021 | 323 | 0.310 |
Why?
|
| United States | 28 | 2021 | 67905 | 0.310 |
Why?
|
| Neoplasms | 14 | 2023 | 20528 | 0.310 |
Why?
|
| Calcifediol | 2 | 2019 | 175 | 0.310 |
Why?
|
| Obesity | 9 | 2023 | 12248 | 0.300 |
Why?
|
| Lymph Nodes | 2 | 2020 | 3424 | 0.300 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2011 | 624 | 0.300 |
Why?
|
| Chromosomes, Human, Pair 1 | 3 | 2016 | 678 | 0.300 |
Why?
|
| Adiponectin | 1 | 2012 | 1089 | 0.300 |
Why?
|
| Palliative Care | 2 | 2015 | 3286 | 0.290 |
Why?
|
| Germ-Line Mutation | 6 | 2022 | 1727 | 0.290 |
Why?
|
| Colonic Neoplasms | 4 | 2019 | 2533 | 0.290 |
Why?
|
| Autophagy | 1 | 2014 | 1314 | 0.290 |
Why?
|
| Neoplasm Staging | 12 | 2019 | 11145 | 0.280 |
Why?
|
| Intestinal Obstruction | 1 | 2009 | 421 | 0.280 |
Why?
|
| Aspirin | 1 | 2017 | 3190 | 0.280 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2008 | 2028 | 0.270 |
Why?
|
| Insulin-Secreting Cells | 1 | 2013 | 972 | 0.270 |
Why?
|
| Feeding Behavior | 4 | 2021 | 3158 | 0.260 |
Why?
|
| Hyperglycemia | 1 | 2013 | 1356 | 0.260 |
Why?
|
| Folic Acid | 2 | 2008 | 1252 | 0.260 |
Why?
|
| HSP90 Heat-Shock Proteins | 2 | 2020 | 453 | 0.250 |
Why?
|
| Incidence | 11 | 2023 | 20731 | 0.250 |
Why?
|
| Nurses | 4 | 2017 | 2376 | 0.250 |
Why?
|
| Muscle, Skeletal | 1 | 2019 | 4931 | 0.250 |
Why?
|
| Cisplatin | 1 | 2010 | 1654 | 0.250 |
Why?
|
| Models, Genetic | 4 | 2020 | 3516 | 0.240 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2020 | 880 | 0.240 |
Why?
|
| Lung Neoplasms | 6 | 2021 | 12539 | 0.240 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2014 | 2091 | 0.230 |
Why?
|
| Bone Neoplasms | 2 | 2015 | 2578 | 0.230 |
Why?
|
| Insulin Resistance | 2 | 2013 | 3884 | 0.220 |
Why?
|
| MAP Kinase Signaling System | 2 | 2021 | 1571 | 0.220 |
Why?
|
| Claudins | 1 | 2023 | 121 | 0.220 |
Why?
|
| Attitude to Death | 1 | 2005 | 378 | 0.220 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2021 | 1633 | 0.220 |
Why?
|
| Chymotrypsin | 1 | 2021 | 152 | 0.220 |
Why?
|
| Biliary Tract | 1 | 2022 | 140 | 0.210 |
Why?
|
| Triazoles | 2 | 2020 | 915 | 0.210 |
Why?
|
| Gene Regulatory Networks | 3 | 2021 | 1699 | 0.210 |
Why?
|
| Acetonitriles | 1 | 2021 | 51 | 0.210 |
Why?
|
| Digestive System Neoplasms | 1 | 2021 | 88 | 0.210 |
Why?
|
| Protein Kinases | 1 | 2008 | 1665 | 0.210 |
Why?
|
| Multifactorial Inheritance | 2 | 2020 | 1153 | 0.200 |
Why?
|
| Dietary Fats | 1 | 2009 | 2048 | 0.200 |
Why?
|
| CA-19-9 Antigen | 1 | 2020 | 97 | 0.200 |
Why?
|
| Risk Assessment | 12 | 2020 | 23464 | 0.200 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2008 | 2074 | 0.200 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2023 | 986 | 0.200 |
Why?
|
| Vitamins | 2 | 2019 | 1517 | 0.200 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2021 | 5198 | 0.200 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2023 | 471 | 0.190 |
Why?
|
| Gallstones | 1 | 2022 | 279 | 0.190 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2020 | 150 | 0.190 |
Why?
|
| Pinocytosis | 1 | 2019 | 73 | 0.190 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2020 | 130 | 0.180 |
Why?
|
| Vacuolar Proton-Translocating ATPases | 1 | 2020 | 192 | 0.180 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2020 | 227 | 0.180 |
Why?
|
| Histamine H2 Antagonists | 1 | 2020 | 169 | 0.180 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2021 | 225 | 0.180 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2021 | 4912 | 0.180 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2019 | 82 | 0.170 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2021 | 248 | 0.170 |
Why?
|
| Linkage Disequilibrium | 7 | 2021 | 2066 | 0.170 |
Why?
|
| Cell Line, Tumor | 12 | 2021 | 16736 | 0.170 |
Why?
|
| Mouth | 1 | 2021 | 421 | 0.170 |
Why?
|
| Rectal Neoplasms | 1 | 2007 | 1121 | 0.170 |
Why?
|
| Cell-Penetrating Peptides | 1 | 2018 | 46 | 0.170 |
Why?
|
| Treatment Outcome | 14 | 2020 | 62004 | 0.170 |
Why?
|
| Mucoproteins | 1 | 2017 | 50 | 0.160 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2018 | 77 | 0.160 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2020 | 397 | 0.160 |
Why?
|
| Pancreatic Cyst | 2 | 2020 | 351 | 0.160 |
Why?
|
| Pulmonary Embolism | 1 | 2010 | 2360 | 0.160 |
Why?
|
| Lymphatic Metastasis | 3 | 2020 | 2968 | 0.160 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 2 | 2008 | 218 | 0.160 |
Why?
|
| BRCA2 Protein | 1 | 2022 | 704 | 0.160 |
Why?
|
| Genetic Counseling | 1 | 2021 | 578 | 0.160 |
Why?
|
| Outpatients | 2 | 2022 | 1371 | 0.150 |
Why?
|
| Radiography, Abdominal | 1 | 2020 | 583 | 0.150 |
Why?
|
| Sequence Deletion | 1 | 2021 | 1550 | 0.150 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2020 | 336 | 0.150 |
Why?
|
| Diet | 3 | 2021 | 7565 | 0.150 |
Why?
|
| Aconitic Acid | 1 | 2016 | 15 | 0.150 |
Why?
|
| Chemokine CCL2 | 1 | 2019 | 655 | 0.150 |
Why?
|
| Isocitrates | 1 | 2016 | 25 | 0.150 |
Why?
|
| Insulin-Like Growth Factor II | 2 | 2008 | 273 | 0.150 |
Why?
|
| Telomere | 2 | 2019 | 842 | 0.150 |
Why?
|
| Cotinine | 1 | 2017 | 204 | 0.150 |
Why?
|
| Lipid Peroxidation | 1 | 2017 | 312 | 0.150 |
Why?
|
| Esophageal Neoplasms | 2 | 2020 | 1509 | 0.150 |
Why?
|
| Glypicans | 1 | 2015 | 28 | 0.150 |
Why?
|
| Glutathione Peroxidase | 1 | 2017 | 261 | 0.140 |
Why?
|
| Maximum Tolerated Dose | 2 | 2016 | 903 | 0.140 |
Why?
|
| Respiratory Tract Diseases | 1 | 2021 | 715 | 0.140 |
Why?
|
| Models, Statistical | 4 | 2020 | 5064 | 0.140 |
Why?
|
| Hyperinsulinism | 1 | 2019 | 412 | 0.140 |
Why?
|
| Organoids | 2 | 2018 | 669 | 0.140 |
Why?
|
| BRCA1 Protein | 1 | 2022 | 1047 | 0.140 |
Why?
|
| RNA Splicing | 1 | 2020 | 872 | 0.140 |
Why?
|
| Proton Pump Inhibitors | 1 | 2020 | 480 | 0.140 |
Why?
|
| Pancreatic Ducts | 1 | 2017 | 333 | 0.140 |
Why?
|
| Iron | 2 | 2021 | 1735 | 0.140 |
Why?
|
| Sequence Analysis, RNA | 3 | 2018 | 2016 | 0.140 |
Why?
|
| DNA Methylation | 4 | 2022 | 4078 | 0.140 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2016 | 368 | 0.140 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2018 | 3689 | 0.140 |
Why?
|
| Genetic Association Studies | 2 | 2017 | 2720 | 0.140 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 901 | 0.140 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2017 | 194 | 0.130 |
Why?
|
| Risk | 5 | 2020 | 9801 | 0.130 |
Why?
|
| Review Literature as Topic | 1 | 2016 | 323 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2016 | 464 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2023 | 11090 | 0.130 |
Why?
|
| Blood Specimen Collection | 1 | 2016 | 247 | 0.130 |
Why?
|
| Interdisciplinary Communication | 1 | 2021 | 982 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2015 | 331 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 3 | 2021 | 2824 | 0.130 |
Why?
|
| Preoperative Period | 1 | 2016 | 554 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2015 | 322 | 0.130 |
Why?
|
| Chromosomes, Human, X | 1 | 2016 | 309 | 0.130 |
Why?
|
| Diet, Mediterranean | 1 | 2020 | 615 | 0.130 |
Why?
|
| RNA, Neoplasm | 1 | 2017 | 774 | 0.130 |
Why?
|
| Gene Frequency | 5 | 2015 | 3722 | 0.130 |
Why?
|
| Cholecalciferol | 1 | 2019 | 498 | 0.130 |
Why?
|
| Logistic Models | 5 | 2013 | 13618 | 0.130 |
Why?
|
| X Chromosome Inactivation | 1 | 2016 | 235 | 0.120 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2017 | 502 | 0.120 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2021 | 1941 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2015 | 438 | 0.120 |
Why?
|
| Testicular Neoplasms | 2 | 2017 | 767 | 0.120 |
Why?
|
| Mice, 129 Strain | 1 | 2014 | 401 | 0.120 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2018 | 580 | 0.120 |
Why?
|
| Fatty Acids | 1 | 2021 | 1746 | 0.120 |
Why?
|
| Signal Transduction | 9 | 2021 | 23729 | 0.120 |
Why?
|
| Ovarian Neoplasms | 3 | 2016 | 4751 | 0.120 |
Why?
|
| Small Molecule Libraries | 1 | 2019 | 725 | 0.120 |
Why?
|
| Disease Progression | 6 | 2020 | 13215 | 0.120 |
Why?
|
| Terminal Care | 1 | 2005 | 1641 | 0.120 |
Why?
|
| Proinsulin | 1 | 2013 | 132 | 0.120 |
Why?
|
| Fatal Outcome | 2 | 2011 | 1879 | 0.120 |
Why?
|
| Blood Glucose | 2 | 2021 | 6259 | 0.120 |
Why?
|
| Single-Cell Analysis | 2 | 2021 | 2129 | 0.120 |
Why?
|
| RNA | 1 | 2023 | 2613 | 0.120 |
Why?
|
| Cardiovascular Diseases | 4 | 2022 | 14438 | 0.110 |
Why?
|
| Lipid Metabolism | 1 | 2021 | 1990 | 0.110 |
Why?
|
| Retrospective Studies | 9 | 2022 | 72443 | 0.110 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 1594 | 0.110 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 986 | 0.110 |
Why?
|
| DNA Repair | 2 | 2021 | 2034 | 0.110 |
Why?
|
| Obesity, Abdominal | 1 | 2015 | 335 | 0.110 |
Why?
|
| Europe | 3 | 2015 | 3343 | 0.110 |
Why?
|
| Drug Administration Schedule | 2 | 2017 | 5031 | 0.110 |
Why?
|
| Combined Modality Therapy | 4 | 2019 | 8890 | 0.110 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2020 | 2977 | 0.110 |
Why?
|
| Administration, Oral | 3 | 2011 | 3956 | 0.110 |
Why?
|
| Phenotype | 3 | 2023 | 16311 | 0.110 |
Why?
|
| Carcinoma | 2 | 2016 | 2321 | 0.110 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 3574 | 0.110 |
Why?
|
| GPI-Linked Proteins | 1 | 2013 | 441 | 0.110 |
Why?
|
| beta Karyopherins | 1 | 2011 | 47 | 0.110 |
Why?
|
| Energy Intake | 2 | 2017 | 2153 | 0.110 |
Why?
|
| Nuts | 1 | 2013 | 255 | 0.100 |
Why?
|
| Time Factors | 6 | 2017 | 40875 | 0.100 |
Why?
|
| Physician-Patient Relations | 1 | 2005 | 3318 | 0.100 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2015 | 814 | 0.100 |
Why?
|
| Chromosome Aberrations | 2 | 2015 | 1808 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2020 | 2985 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2012 | 777 | 0.100 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2011 | 2096 | 0.100 |
Why?
|
| Piperazines | 1 | 2021 | 2524 | 0.100 |
Why?
|
| C-Peptide | 2 | 2008 | 408 | 0.100 |
Why?
|
| Health Surveys | 2 | 2017 | 4036 | 0.100 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2011 | 116 | 0.100 |
Why?
|
| Carbohydrate Metabolism | 1 | 2011 | 282 | 0.100 |
Why?
|
| Glycosyltransferases | 1 | 2010 | 110 | 0.100 |
Why?
|
| Membrane Transport Proteins | 1 | 2016 | 1020 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2017 | 9596 | 0.100 |
Why?
|
| Reproducibility of Results | 6 | 2021 | 19537 | 0.090 |
Why?
|
| Immunoconjugates | 1 | 2016 | 830 | 0.090 |
Why?
|
| Epidemiology | 1 | 2013 | 295 | 0.090 |
Why?
|
| Flow Cytometry | 1 | 2020 | 6093 | 0.090 |
Why?
|
| Breast Neoplasms | 2 | 2019 | 20062 | 0.090 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2011 | 483 | 0.090 |
Why?
|
| Women's Health | 2 | 2016 | 1954 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2020 | 2947 | 0.090 |
Why?
|
| Stathmin | 1 | 2009 | 61 | 0.090 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 966 | 0.090 |
Why?
|
| Melanoma | 3 | 2017 | 5250 | 0.090 |
Why?
|
| Pathology, Molecular | 1 | 2013 | 348 | 0.090 |
Why?
|
| Chromatography, Liquid | 1 | 2013 | 961 | 0.090 |
Why?
|
| Carbon | 1 | 2013 | 656 | 0.090 |
Why?
|
| Diet Surveys | 2 | 2013 | 1157 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2021 | 2930 | 0.090 |
Why?
|
| Oncogene Protein v-akt | 1 | 2008 | 141 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2022 | 3551 | 0.090 |
Why?
|
| Mice | 9 | 2021 | 80375 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 5 | 2021 | 22665 | 0.090 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 4296 | 0.090 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2014 | 1104 | 0.090 |
Why?
|
| Paclitaxel | 3 | 2023 | 1626 | 0.090 |
Why?
|
| C-Reactive Protein | 2 | 2013 | 3713 | 0.090 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2009 | 287 | 0.080 |
Why?
|
| Observer Variation | 1 | 2014 | 2676 | 0.080 |
Why?
|
| Angioedema | 1 | 2009 | 183 | 0.080 |
Why?
|
| Sex Characteristics | 2 | 2016 | 2550 | 0.080 |
Why?
|
| Urticaria | 1 | 2009 | 160 | 0.080 |
Why?
|
| Pancreatitis, Chronic | 2 | 2020 | 259 | 0.080 |
Why?
|
| Gene Expression | 2 | 2020 | 7954 | 0.080 |
Why?
|
| Age of Onset | 1 | 2014 | 3316 | 0.080 |
Why?
|
| Metabolomics | 1 | 2016 | 1392 | 0.080 |
Why?
|
| Epigenomics | 1 | 2013 | 806 | 0.080 |
Why?
|
| Tubulin | 1 | 2011 | 759 | 0.080 |
Why?
|
| Immunohistochemistry | 3 | 2018 | 11689 | 0.080 |
Why?
|
| Neuroendocrine Tumors | 1 | 2012 | 532 | 0.080 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2013 | 1119 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 11201 | 0.080 |
Why?
|
| Postprandial Period | 3 | 2017 | 306 | 0.080 |
Why?
|
| Endometrial Neoplasms | 1 | 2016 | 1343 | 0.080 |
Why?
|
| Eating | 1 | 2013 | 1454 | 0.080 |
Why?
|
| Nanoparticles | 1 | 2018 | 1900 | 0.080 |
Why?
|
| Animals | 12 | 2021 | 169420 | 0.080 |
Why?
|
| China | 1 | 2012 | 2241 | 0.080 |
Why?
|
| Quinazolines | 3 | 2012 | 1408 | 0.070 |
Why?
|
| Dietary Supplements | 1 | 2019 | 3110 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2020 | 752 | 0.070 |
Why?
|
| Mice, Knockout | 3 | 2020 | 15059 | 0.070 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 2775 | 0.070 |
Why?
|
| Prodrugs | 1 | 2008 | 273 | 0.070 |
Why?
|
| Disease Susceptibility | 2 | 2014 | 1780 | 0.070 |
Why?
|
| Vitamin B 6 | 1 | 2007 | 222 | 0.070 |
Why?
|
| Dietary Carbohydrates | 1 | 2011 | 913 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 13643 | 0.070 |
Why?
|
| Databases, Genetic | 3 | 2020 | 1801 | 0.070 |
Why?
|
| Genome, Human | 2 | 2021 | 4471 | 0.070 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2020 | 2288 | 0.070 |
Why?
|
| Lymphocytes | 1 | 2014 | 2737 | 0.070 |
Why?
|
| Young Adult | 5 | 2021 | 56226 | 0.070 |
Why?
|
| Albumins | 2 | 2019 | 564 | 0.070 |
Why?
|
| Proteins | 2 | 2018 | 6070 | 0.070 |
Why?
|
| Aging | 2 | 2016 | 8350 | 0.070 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2010 | 509 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 2 | 2016 | 4919 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2005 | 5623 | 0.070 |
Why?
|
| Hematologic Neoplasms | 1 | 2016 | 1688 | 0.070 |
Why?
|
| Geriatric Assessment | 1 | 2013 | 1312 | 0.070 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 1987 | 0.070 |
Why?
|
| Mass Screening | 1 | 2020 | 5209 | 0.070 |
Why?
|
| Prednisone | 1 | 2009 | 1546 | 0.070 |
Why?
|
| Hypothyroidism | 1 | 2009 | 649 | 0.060 |
Why?
|
| Membrane Proteins | 3 | 2021 | 8047 | 0.060 |
Why?
|
| Vitamin B 12 | 1 | 2007 | 511 | 0.060 |
Why?
|
| Referral and Consultation | 1 | 2017 | 3451 | 0.060 |
Why?
|
| Homocysteine | 1 | 2007 | 659 | 0.060 |
Why?
|
| Research Design | 2 | 2010 | 5902 | 0.060 |
Why?
|
| Microsatellite Instability | 1 | 2007 | 664 | 0.060 |
Why?
|
| Staurosporine | 1 | 2004 | 254 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2020 | 9004 | 0.060 |
Why?
|
| Data Collection | 1 | 2013 | 3317 | 0.060 |
Why?
|
| Cytokines | 1 | 2018 | 7190 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2013 | 3171 | 0.060 |
Why?
|
| Confidence Intervals | 1 | 2009 | 2993 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2011 | 3294 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2020 | 18199 | 0.060 |
Why?
|
| Mucin 5AC | 1 | 2023 | 97 | 0.060 |
Why?
|
| Indoles | 1 | 2011 | 1845 | 0.060 |
Why?
|
| CpG Islands | 1 | 2007 | 1171 | 0.060 |
Why?
|
| Motor Activity | 2 | 2010 | 2774 | 0.060 |
Why?
|
| Medical Oncology | 2 | 2023 | 2118 | 0.060 |
Why?
|
| Stem Cell Transplantation | 1 | 2011 | 1639 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2007 | 2292 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 3947 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 2017 | 546 | 0.050 |
Why?
|
| Cyclin T | 1 | 2021 | 21 | 0.050 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 3542 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 3633 | 0.050 |
Why?
|
| Stearoyl-CoA Desaturase | 1 | 2021 | 91 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2007 | 1834 | 0.050 |
Why?
|
| Exercise | 3 | 2021 | 5427 | 0.050 |
Why?
|
| Computer Simulation | 3 | 2021 | 6105 | 0.050 |
Why?
|
| Skin Neoplasms | 2 | 2017 | 5318 | 0.050 |
Why?
|
| Empathy | 1 | 2005 | 447 | 0.050 |
Why?
|
| Endocrine Cells | 1 | 2020 | 12 | 0.050 |
Why?
|
| Sex Distribution | 2 | 2020 | 2371 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2022 | 8805 | 0.050 |
Why?
|
| Exocrine Glands | 1 | 2020 | 50 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2019 | 6484 | 0.050 |
Why?
|
| Biotinylation | 1 | 2020 | 184 | 0.050 |
Why?
|
|